Personalized faricimab for new polypoidal choroidal vasculopathy
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have active polyp-like lesions in the central part of your retina (macula) causing fluid or bleeding
- Your vision is reduced but not worse than about 20/320 and not better than 20/40 on an eye chart
- You have not had any previous eye injections for this condition
- You do not have any uncontrolled health problems like active cancer, high blood pressure, or recent stroke or heart attack
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.